Noncirrhotic portal hypertension in HIV-infected patients: A case control evaluation and review of the literature

AIDS Patient Care and STDs

Volumn 24, Issue 11, 2010, Pages 697-703

  Cesari, Miriam ^a   Schiavini, Monica ^a   Marchetti, Giulia ^b   Caramma, Ilaria ^a   Ortu, Massimiliano ^a   Franzetti, Fabio ^a   Galli, Massimo ^a   Antinori, Spinello ^a   Milazzo, Laura ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CD14 ANTIGEN; GAMMA GLUTAMYLTRANSFERASE; PROTEIN C; PROTEIN S; SERUM ALBUMIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASCITES; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ESOPHAGUS VARICES BLEEDING; EVALUATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IDIOPATHIC DISEASE; INTERNATIONAL NORMALIZED RATIO; LIVER HYPERPLASIA; MALE; NONCIRRHOTIC PORTAL HYPERTENSION; PORTAL HYPERTENSION; PORTAL VEIN THROMBOSIS; THROMBOCYTOPENIA;

ADULT; AGED; ANTI-HIV AGENTS; CASE-CONTROL STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; HYPERTENSION, PORTAL; LIVER; LIVER DISEASES; MALE; MIDDLE AGED; PORTAL SYSTEM;

EID: 78149429491     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2010.0160     Document Type: Article

References (41)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
2. The CASCADE Collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet 2000;355:1158-1159.
3. Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodefi-ciency virus: the D:A:D study. Arch Intern Med 2006;166: 1632-1641. (Pubitemid 44232373)
4. Bica I, McGovern B, Dhaz R, et al. Increasing mortality due to end-stage liver disease in patients with human immuno-deficiency virus infection. Clin Infect Dis 2001;32:492-497. (Pubitemid 32173638)
5. Mart́in-Carbonero L, Soriano V, Valencia E, Garćia-Samaniego J, López M, González-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admission and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 2001;17: 1467-1471. (Pubitemid 33116749)
6. Rosenthal E, Poirée M, Pradier C, Perronne C, et al. Mor-tality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003;17: 1803-1809. (Pubitemid 37000098)
7. Lemoine M, Barbu V, Girard PM, et al. Altered hepatic ex-pression of SREBP-1 and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients. AIDS 2006;20:387-395.
8. Wan DW, Marks K, Yantiss RK, Talal AH. Autoimmune hepatitis in the HIV-infected patient: a therapeutic dilemma. AIDS Patient Care STDs 2009;23:407-413.
9. Maida I, Núñez M, Ríos MJ, et al. Severe liver disease as-sociated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr 2006;42:177-182. (Pubitemid 43884712)
10. Arey B, Markov M, Ravi J, Prevette E, Batts K, Nadir A. Nodular regenerative hyperplasia of liver as a consequence of ART. AIDS 2007;21:1066-1068. (Pubitemid 46684349)
11. Chang PE, Miquel R, Blanco JL, et al. Idiopathic portal hy-pertension in patients with HIV infection treated with highly active antiretroviral therapy. Am J Gastroenterol 2009;104: 1707-1714.
12. Chang PE, Garcia-Pagan JC. Idiopathic noncirrhotic portal hypertension in HIV-infected patients. Clin Infect Dis 2010;50:127-128.
13. Ding A, Lee A, Callender M, Loughrey M, Quah SP, Dins-more WW. Hepatic encephalopathy as an unusual late complication of transjugular intrahepatic portosystemic shunt insertion for non-cirrhotic portal hypertension caused by nodular regenerative hyperplasia in an HIV-positive patient on highly active antiretroviral therapy. Int J STD AIDS 2010;21:71-72.
14. Dinh MH, Stosor V, Rao SM, Miller FH, Green RM. Crypto-genic liver disease in HIV-seropositive men. HIV Med 2009; 10:447-453.
15. Fernandez-Miranda C, Colina F, Delgado JM, Lopez-Carreira M. Diffuse nodular regenerative hyperplasia of the liver associated with human immunodeficiency virus and visceral leishmaniasis. Am J Gastroenterol 1993;88:433-435. (Pubitemid 23085858)
16. Garvey LJ, Thomson EC, Lloyd J, Cooke GS, Goldin RD, Main J. Response to Mallet et al. Nodular regenerative hy-perplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS 2007;21:1494-1495. (Pubitemid 46988016)
17. Kochin I, Magid M, Arnon R, Glasscock A, Kerkar N, Miloh T. Variceal bleeding in an adolescent with HIV diagnosed with hepatoportal sclerosis and nodular regenerative hy-perplasia. J Pediatr Gastroenterol Nutr 2010;50:340-343.
18. Kovari H, Ledergerber B, Peter U, et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: A nested case-control study. Clin Infect Dis 2009;49:626-635.
19. Maida I, Garcia-Gasco P, Sotgiu G, et al. Antiretroviral-associated portal hypertension: A new clinical condition? Pre-valence, predictors and outcome. Antivir Ther 2008;13:103-107. (Pubitemid 351541679)
20. Mallet V, Blanchard P, Verkarre V, et al. Nodular regener-ative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS 2007;21:187-192. (Pubitemid 46036926)
21. Mallet VO, Bralet MP, Pol S. Response to Schiano et al. Hepatoportal sclerosis as a cause of noncirrhotic portal hy-pertension in patients with HIV. Am J Gastroenterol 2008; 103:808-809.
22. Mallet VO, Varthaman A, Lasne D, et al. Acquired protein S deficiency leads to obliterative portal venopathy and to compensatory nodular regenerative hyperplasia in HIV-infected patients. AIDS 2009;23:1511-1518.
23. Panos G, Farouk L, Stebbing J, et al. Cryptogenic pseudo-cirrhosis: a new clinical syndrome of noncirrhotic portal hypertension (unassociated with advanced fibrosis) that can be detected by transient elastography in patients with HIV. J Acquir Immune Defic Syndr 2009;52:525-527.
24. Podevin P, Spiridon G, Terris B, et al. Nodular regenerative hyperplasia of the liver after IL-2 therapy in an HIV-infected patient. AIDS 2006;20:313-315.
25. Saifee S, Joelson D, Braude J, et al. Noncirrhotic portal hy-pertension in patients with human immunodeficiency virus-1 infection. Clin Gastroenterol Hepatol 2008;6:1167-1169.
26. Sandrine PF, Sylvie A, André E, Abdoulaye D, Bernard L, André C. Nodular regenerative hyperplasia: a new serious antiretroviral drugs side effect? AIDS 2007;21:1498-1499. (Pubitemid 46988019)
27. Schiano TD, Kotler DP, Ferran E, Fiel MI. Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol 2007;102:2536-2540. (Pubitemid 47631766)
28. Tateo M, Sebagh M, Bralet MP, et al. A new indication for liver transplantation: nodular regenerative hyperplasia in human immunodeficiency virus-infected patients. Liver Transpl 2008;14:1194-1198.
29. Vispo E, Moreno A, Maida I, Barreiro P, Cuevas A, Albertos S, et al. Noncirrhotic portal hypertension in HIV-infected patients: Unique clinical and pathological findings. AIDS 15;24:1171-1176.
30. Arvanitaki M, Adler M. Nodular regenerative hyperplasia of the liver. A review of 14 cases. Hepatogastroenterology 2001;48:1425-1429. (Pubitemid 33010439)
31. Steiner PE. Nodular regenerative hyperplasia of the liver. Am J Pathol 1959;35:943-953.
32. Stromeyer FW, Ishak KG. Nodular transformation (nodular "regenerative" hyperplasia) of the liver. A clinicopathologic study of 30 cases. Hum Pathol 1981;12:60-71. (Pubitemid 12239395)
33. Reshamwala PA, Kleiner DE, Heller T. Nodular regenerative hyperplasia: Not all nodules are created equal. Hepatology 2006;44:7-14. (Pubitemid 44049133)
34. Albillos A, de la Hera A, González M, et al. Increased li-popolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepa-tology 2003;37:208-217. (Pubitemid 36042162)
35. Fraquelli M, Rigamonti C, Casazza G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007;56:968-973. (Pubitemid 46999083)
36. Hillaire S, Bonte E, Denninger MH, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: A re-evaluation in 28 patients. Gut 2002;51:275-280. (Pubitemid 34791461)
37. Ibarrola C, Colina F. Clinicopathological features of nine cases of non-cirrhotic portal hypertension: Current defini-tions and criteria are inadequate. Histopathology 2003; 42:251-264. (Pubitemid 36356858)
38. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology 2006;43(2 Suppl 1):S99-S112. (Pubitemid 43303974)
39. Yee SB, Harkema JR, Ganey PE, Roth RA. The coagulation system contributes to synergistic liver injury from exposure to monocrotaline and bacterial lipopolysaccharide. Toxicol Sci 2003;74:457-469. (Pubitemid 36958313)
40. Balagopal A, Philp FH, Astemborski J, et al. Human immu-nodeficiency virus-related microbial translocation and pro-gression of hepatitis C. Gastroenterology 2008;135:226-233. (Pubitemid 351899010)
41. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12:1365-1371.